Evidence map›Paper›PMID 24759736›Full record

ArticlePloS one2014

Brd4 is essential for IL-1β-induced inflammation in human airway epithelial cells.

Younis M Khan, Paul Kirkham, Peter J Barnes, Ian M Adcock

Registry-linked trialOpen access · goldAbstract read
In one paragraph

Article in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03655704 (Apabetalone for Pulmonary Arterial Hypertension), which is not on this map. Cited by 64 papers.

0numbers the graph read from it
0cells of the map it votes in
64citing papers in PubMed
5.0field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03655704 early_phase1completednot on this mapstarted 2019, after this paper: background citation

Apabetalone for Pulmonary Arterial Hypertension: a Pilot Study

TypeinterventionalSponsorSteeve ProvencherRan2019 to 2021Enrolled7ConditionsPulmonary Arterial HypertensionArmsApabetalone
3 · Its place in the literature

Who cites it

64 citing papers in PubMed, 106 citations in OpenAlex.

  1. Review
  2. Senotherapy for chronic lung disease.Pharmacological reviews · 2025
    Review
  3. Article
  4. Article
  5. An updated patent review of BRD4 degraders.Expert opinion on therapeutic patents · 2024
    Review
  6. Article
  7. Review
  8. Article
  9. Article
  10. BRD4 as a Therapeutic Target in Pulmonary Diseases.International journal of molecular sciences · 2023
    Review
  11. MAPK/MAK/MRK overlapping kinase (MOK) controls microglial inflammatory/type-I IFN responses via Brd4 and is involved in ALS.Proceedings of the National Academy of Sciences of the United States of America · 2023
    Article
  12. Article
  13. Article
  14. Prevalence and Mechanisms of Mucus Accumulation in COVID-19 Lung Disease.American journal of respiratory and critical care medicine · 2022
    Article
  15. Review
  16. Article
  17. Review
  18. Article
  19. Review
  20. Article

4 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Younis M KhanAirways Disease Section, National Heart & Lung Institute, Imperial College London, London, United Kingdom.
Paul KirkhamSchool of Applied Sciences, University of Wolverhampton, Wolverhampton, United Kingdom.
Peter J BarnesAirways Disease Section, National Heart & Lung Institute, Imperial College London, London, United Kingdom.
Ian M AdcockAirways Disease Section, National Heart & Lung Institute, Imperial College London, London, United Kingdom.
Imperial College London · GBUniversity of Wolverhampton · GB

Funding

Medical Research Council G1000758Wellcome TrustWellcome Trust 093080/Z/10/Z
6 · The paper itself

Abstract

backgroundChronic inflammation and oxidative stress are key features of chronic obstructive pulmonary disease (COPD). Oxidative stress enhances COPD inflammation under the control of the pro-inflammatory redox-sensitive transcription factor nuclear factor-kappaB (NF-κB). Histone acetylation plays a critical role in chronic inflammation and bromodomain and extra terminal (BET) proteins act as "readers" of acetylated histones. Therefore, we examined the role of BET proteins in particular Brd2 and Brd4 and their inhibitors (JQ1 and PFI-1) in oxidative stress- enhanced inflammation in human bronchial epithelial cells.

methodsHuman primary epithelial (NHBE) cells and BEAS-2B cell lines were stimulated with IL-1β (inflammatory stimulus) in the presence or absence of H2O2 (oxidative stress) and the effect of pre-treatment with bromodomain inhibitors (JQ1 and PFI-1) was investigated. Pro-inflammatory mediators (CXCL8 and IL-6) were measured by ELISA and transcripts by RT-PCR. H3 and H4 acetylation and recruitment of p65 and Brd4 to the native IL-8 and IL-6 promoters was investigated using chromatin immunoprecipitation (ChIP). The impact of Brd2 and Brd4 siRNA knockdown on inflammatory mediators was also investigated.

resultH2O2 enhanced IL1β-induced IL-6 and CXCL8 expression in NHBE and BEAS-2B cells whereas H2O2 alone did not have any affect. H3 acetylation at the IL-6 and IL-8 promoters was associated with recruitment of p65 and Brd4 proteins. Although p65 acetylation was increased this was not directly targeted by Brd4. The BET inhibitors JQ1 and PFI-1 significantly reduced IL-6 and CXCL8 expression whereas no effect was seen with the inactive enantiomer JQ1(-). Brd4, but not Brd2, knockdown markedly reduced IL-6 and CXCL8 release. JQ1 also inhibited p65 and Brd4 recruitment to the IL-6 and IL-8 promoters.

conclusionOxidative stress enhanced IL1β-induced IL-6 and CXCL8 expression was significantly reduced by Brd4 inhibition. Brd4 plays an important role in the regulation of inflammatory genes and provides a potential novel anti-inflammatory target.

Indexed as

AzepinesBromodomain Containing ProteinsCell Cycle ProteinsCell LineChromatin ImmunoprecipitationEnzyme-Linked Immunosorbent AssayEpithelial CellsHumansHydrogen PeroxideInflammationInterleukin-1betaInterleukin-6Interleukin-8Nuclear ProteinsProtein Serine-Threonine KinasesTranscription FactorsAzepinesBRD2 protein, humanBRD4 protein, humanBromodomain Containing ProteinsCell Cycle ProteinsHydrogen PeroxideInterleukin-1betaInterleukin-6Interleukin-8(+)-JQ1 compoundNuclear ProteinsProtein Serine-Threonine KinasesTranscription FactorsTriazoles

Identifiers

PMID24759736
PMCPMC3997389
OpenAlexW2037896546

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.